Robert Silver, MD
Endocrinology, Diabetes & Metabolism · Brooklyn, NYNPI 1538268123
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (46.0%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Novo Nordisk accounts for 77.0% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2019 at $41,085 and has fallen 51.1% since, to $20,111 in 2025. Among endocrinology, diabetes & metabolism clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 151 payments — averaging $952.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$111K
- Vertex$15K
- AstraZeneca$9K
- Novo Nordisk AS$7K
- Medtronic$1K
- Eli Lilly$458
- plus $220 from 3 others
Across 1,621 payments — averaging $735.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$605K
- Novo Nordisk AS$577K
- Kowa Research Institute, Inc.$10K
- Merck$171
What the payments were for
- Consulting fees$56,68639%
- Speaking & faculty fees$66,21246%
- Travel & lodging$17,18012%
- Food & beverage$3,7583%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 97 | $110,831 |
| Vertex | 24 | $15,277 |
| AstraZeneca | 16 | $9,047 |
| Novo Nordisk AS | 6 | $6,733 |
| Medtronic | 3 | $1,287 |
| Eli Lilly | 1 | $458 |
| Amgen | 1 | $86 |
| Lilly USA, LLC | 2 | $78 |
| Tandem Diabetes Care, Inc. | 1 | $56 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$36,515
- RYBELSUS$24,057
- Victoza$14,920
- Ryzodeg 70/30$13,241
- Tresiba$10,778
- FARXIGA$8,701
- Minimed 670G System$1,250
- Xultophy 100/3.6$1,190
How this compares
$143,852 in reported general payments places this provider in the 95th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 70 | $105,369 |
| JardianceEmpagliflozin | 49 | $50,175 |
| JanuviaSitagliptin Phosphate | 35 | $42,302 |
| TrulicityDulaglutide | 18 | $30,454 |
| MounjaroTirzepatide | 18 | $22,558 |
| JanumetSitagliptin Phos/Metformin Hcl | 19 | $13,818 |
| Cinacalcet Hcl | 22 | $8,009 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 53 | $5,436 |
| Novolog FlexpenInsulin Aspart | 23 | $3,241 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 24 | $2,438 |
| Levothyroxine Sodium | 110 | $1,606 |
| Ultra-Fine Mini Pen NeedlePen Needle, Diabetic | 13 | $991 |
| Rosuvastatin Calcium | 26 | $981 |
| Atorvastatin Calcium | 56 | $955 |
| Metformin Hcl | 64 | $464 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $110,831 | $105,36970 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $78 | $53,01236 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
Other endocrinology, diabetes & metabolism in Brooklyn
- Alexander PerkelvaldBrooklyn$302K
- Matvey BrokhinBrooklyn$243K
- Matin SharafatkhahBrooklyn$235K
- Iraklii BuziashviliBrooklyn$104K
- Robert BuschAlbany$2.7M
- Michael ShanikSmithtown$1.2M
- Ajay ChaudhuriBuffalo$888K
- Vinay KapoorManhasset$820K
- John BilezikianNew York$809K
- Barbara HirschManhasset$746K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.